Financial Performance - The company's revenue for Q1 2025 was ¥78,186,465.07, a decrease of 14.84% compared to ¥91,814,686.88 in the same period last year[5] - Net profit attributable to shareholders was ¥12,063,975.22, down 39.35% from ¥19,890,650.72 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥6,267,512.03, reflecting a decline of 49.10% compared to ¥12,313,887.76 in the previous year[5] - Basic and diluted earnings per share decreased by 40.00% to ¥0.12 from ¥0.20 year-on-year[5] - Net profit for the current period is 11,673,597.10, a decrease of 40.4% compared to 19,593,040.69 in the previous period[24] - Operating profit for the current period is 14,300,919.19, down from 23,846,785.88, reflecting a decline of 40.2%[24] - Total comprehensive income for the current period is 11,673,597.10, compared to 19,593,040.69 in the previous period[25] Cash Flow - The net cash flow from operating activities was negative at -¥8,644,285.96, a significant drop of 136.52% from ¥23,671,274.75 in the same period last year[5] - Cash flow from operating activities shows a net outflow of -8,644,285.96, compared to a net inflow of 23,671,274.75 in the previous period[27] - Cash flow from investment activities results in a net outflow of -50,149,819.47, an improvement from -326,688,357.82 in the previous period[28] - The company reported a decrease in cash inflow from operating activities, totaling 97,064,672.74, down from 114,753,819.18[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,480,830,664.33, a slight decrease of 0.06% from ¥2,482,438,025.25 at the end of the previous year[5] - Total current assets increased slightly to ¥1,427,814,741.49 from ¥1,423,545,701.77, a growth of 0.2%[20] - Total liabilities decreased to ¥215,599,582.22 from ¥228,880,540.24, a reduction of 5.8%[21] - The company reported a financial expense of ¥242,468.51, compared to a financial income of -¥1,724,609.95 in the previous period[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,853, with no preferred shareholders[13] - The largest shareholder, Wan Shiping, holds 25.02% of the shares, totaling 25,063,734 shares[13] - The company has no preferred shareholders and no changes in the number of restricted shares during the reporting period[15] Operating Costs and Expenses - Total operating revenue for the current period was ¥78,186,465.07, a decrease of 14.9% compared to ¥91,814,686.88 in the previous period[23] - Total operating costs decreased to ¥72,372,834.27 from ¥78,189,414.84, reflecting a reduction of 7.3%[23] - Operating costs included ¥43,469,650.62 in cost of goods sold, down from ¥48,552,852.60, indicating a decrease of 10.5%[23] - Research and development expenses were ¥4,169,622.11, a decrease of 13.2% from ¥4,804,803.02 in the previous period[23] Cash and Cash Equivalents - The company reported a significant decrease in cash and cash equivalents, down 68.56% to ¥92,804,243.60 from ¥295,179,331.27[9] - Cash and cash equivalents at the end of the period were ¥92,804,243.60, down from ¥295,179,331.27, a decline of 68.6%[19] - Cash and cash equivalents at the end of the period stand at 90,402,668.60, down from 237,281,126.32[28] Financial Expenses and Income - Financial expenses increased by 114.06% to ¥242,468.51 due to higher bank loan interest payments[10] - Other income decreased by 66.04% to ¥904,710.09, primarily due to a reduction in government subsidies received[10] - Total revenue from interest income is 115,402.24, while other income amounts to 904,710.09, contributing to a total of 1,020,112.33[24] Dividend and Interest Payments - Cash paid for dividends and interest surged by 1,313.46%, from ¥18,105.56 to ¥255,914.89, driven by increased interest and discount expenses[11] - Cash paid for debt repayment increased by 1,092.16%, from ¥100,000.00 to ¥1,192,155.00, primarily due to higher bank loan repayments[11] - Cash received from borrowings surged by 11,209.46%, from ¥291,723.44 to ¥32,992,344.35, reflecting an increase in bank loans during the reporting period[11]
东星医疗(301290) - 2025 Q1 - 季度财报